MAIA BIOTECHNOLOGY, INC. financials

MAIA CIK 0001878313

Source: EDGAR filings · Built 2026-06-04T02:27:46Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Working Capital 3.87M 6.32M 2.63M 8.54M 8.53M
Return on Equity (ROE) -942.65% -639.81% -4140.83% -185.35% -137.00%
Return on Assets (ROA) -230.78% -228.99% -261.31% -131.17% -111.04%
Current Ratio 1.66× 2.65× 1.53× 3.61× 4.97×
Effective Tax Rate -0.01% -0.01%
Cash Conversion Ratio 0.84× 0.68× 0.66× 0.77× 0.33×
Accruals Ratio -0.37× -0.74× -0.89× -0.31× -0.75×

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
P/B 24.87× 14.25× 41.62× 4.52×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Revenues 0 0 0
Research and Development Expense 453.75K 10.01M 11.11M 8.93M 3.50M
Operating Expenses 24.27M 16.96M 20.18M 16.18M 7.79M
Operating Income (Loss) -24.27M -16.96M -20.18M -16.18M -7.79M
Income Tax Expense (Benefit) 2.00K 2.00K
Net Income (Loss) Attributable to Parent -22.40M -23.25M
Earnings Per Share, Basic $-0.70 $-1.05 $-1.49 $-1.75 $-2.37
Weighted Average Number of Shares Outstanding, Basic 32.11M 22.20M 13.26M 9.28M 5.28M
Earnings Per Share, Diluted $-0.70 $-1.05 $-1.49 $-1.75 $-2.37
Weighted Average Number of Shares Outstanding, Diluted 32.11M 22.20M 13.26M 9.28M 5.28M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Cash and Cash Equivalents, at Carrying Value 0 0 0 0 0
Assets, Current 9.70M 10.15M 7.56M 11.81M 10.67M
Assets 9.70M 10.16M 7.57M 12.02M 11.33M
Liabilities, Current 5.84M 3.83M 4.94M 3.27M 2.15M
Liabilities 7.33M 6.52M 7.09M 3.51M 2.15M
Stockholders' Equity Attributable to Parent 2.38M 3.63M 477.51K
Common Stock, Shares, Outstanding 38.62M 26.16M 16.99M 10.96M 7.58M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Net Cash Provided by (Used in) Operating Activities -18.84M -15.70M -13.07M -12.10M -4.12M
Net Cash Provided by (Used in) Financing Activities 17.91M 18.18M 9.27M 12.48M 14.03M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MAIA CIK 0001878313), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CHRS

Coherus Oncology, Inc.

LGND

LIGAND PHARMACEUTICALS INCORPORATED

SVRA

Savara Inc.